According to Zhitong Finance App News, Hongbo Pharmaceutical (301230.SZ) announced its 2023 annual results. The company achieved operating income of 490 million yuan, an increase of 2.26% year on year; net profit attributable to shareholders of listed companies was 376.192 million yuan, a year-on-year decrease of 44%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 287.262 million yuan, a year-on-year decrease of 54.14%; basic income per share is 0.35 yuan/share; plans to distribute a dividend of 3.30 yuan (tax included) for every 10 shares to all shareholders and 0 bonus shares (tax included), with capital The Provident Fund transfers 3 shares for every 10 shares of all shareholders.